|
Alpha One Foundation
The Alpha One Foundation is the only national research organization solely dedicated to developing the means to cure and control AAT deficiency and to improve the quality of life for those with the disorder. The strategic program direction and all activities of the Foundation are guided by representatives of the Alpha One Foundation, medical and scientific communities
Toll Free: 877-2-CURE-A1 (877-228-7321)
Web site: www.alphaone.org
Alpha-1 Association
The Alpha-1 Association is a nonprofit organization that exists to help people with AAT deficiency and to act as their advocate. The National Association acts as a clearinghouse of information to assist healthcare professionals and individuals with AAT deficiency. Through this organization, patients will meet other people with AAT deficiency who can provide encouragement to them. Some people meet informally as part of a national support network. There are chapters all across the country, with new ones springing up all the time.
Toll-Free: 800-521-3025
Web site: www.alpha1.org
AlphaNet
AlphaNet is a not-for-profit health management company providing comprehensive services exclusively to the Alpha-1 community. AlphaNet provides enrollment assistance to patients receiving Prolastin® through the Prolastin DirectSM program, and helps coordinate their care. AlphaNet also helps coordinate information on insurance and nursing care, ordering infusion supplies, and additional education and support. In addition, AlphaNet provides free Alpha-1 test kits and information about testing.
Toll-Free: 800-577-2638
Web site: www.alphanet.org
American Lung Association
The American Lung Association can provide information and assistance, especially if you are trying to quit smoking. Their mission is to prevent and fight lung disease through education, community service, advocacy and research, and to seek better treatments and cures.
Toll-Free: 800-LUNG-USA (800-586-4872)
Web site: www.lungusa.org
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|